Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
96 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014', provides an overview of the Uterine Leiomyoma (Uterine Fibroids)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uterine Leiomyoma (Uterine Fibroids) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Uterine Leiomyoma (Uterine Fibroids) Overview 8 Therapeutics Development 9 Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Overview 9 Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis 10 Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Development by Companies 11 Uterine Leiomyoma (Uterine Fibroids) - Therapeutics under Investigation by Universities/Institutes 13 Uterine Leiomyoma (Uterine Fibroids) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Uterine Leiomyoma (Uterine Fibroids) - Products under Development by Companies 17 Uterine Leiomyoma (Uterine Fibroids) - Products under Investigation by Universities/Institutes 18 Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development 19 Euroscreen S.A. 19 Takeda Pharmaceutical Company Limited 20 Neurocrine Biosciences, Inc. 21 Novartis AG 22 Kissei Pharmaceutical Co., Ltd. 23 Bayer AG 24 BioSpecifics Technologies Corp. 25 Repros Therapeutics Inc. 26 Dongkook Pharmaceutical Co., Ltd. 27 HRA Pharma 28 AbbVie Inc. 29 Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 ulipristal acetate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 relugolix - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 elagolix sodium - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 telapristone acetate - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 mifepristone - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KLH-2109 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 vilaprisan - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ESN-364 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 LFA-102 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 collagenase clostridium histolyticum - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 GnRH Antagonists - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 EVE-104 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 triptorelin pamoate biosimilar - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Drugs for Women Health - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Uterine Leiomyoma (Uterine Fibroids) - Recent Pipeline Updates 62 Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects 83 Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products 84 Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones 85 Featured News & Press Releases 85 Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids 85 Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design 85 Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids 85 Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 87 Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 87 Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 88 Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 89 Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 90 Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 91 Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 93 Appendix 95 Methodology 95 Coverage 95 Secondary Research 95 Primary Research 95 Expert Panel Validation 95 Contact Us 96 Disclaimer 96
List of Tables Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2014 9 Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids) - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Investigation by Universities/Institutes, H2 2014 18 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Euroscreen S.A., H2 2014 19 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Neurocrine Biosciences, Inc., H2 2014 21 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Novartis AG, H2 2014 22 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 23 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2014 24 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp., H2 2014 25 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc., H2 2014 26 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 27 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by HRA Pharma, H2 2014 28 Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc., H2 2014 29 Assessment by Monotherapy Products, H2 2014 30 Number of Products by Stage and Target, H2 2014 32 Number of Products by Stage and Mechanism of Action, H2 2014 34 Number of Products by Stage and Route of Administration, H2 2014 36 Number of Products by Stage and Molecule Type, H2 2014 38 Uterine Leiomyoma (Uterine Fibroids) Therapeutics - Recent Pipeline Updates, H2 2014 62 Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2014 83 Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2014 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
